A37 EFFICACY AND SAFETY OF RISANKIZUMAB AS MAINTENANCE THERAPY IN PATIENTS WITH CROHN’S DISEASE: 52 WEEK RESULTS FROM THE PHASE 3 FORTIFY STUDY

por Panaccione, R, Ferrante, M, Feagan, B G, Sandborn, W, Panes, J, Peyrin-Biroulet, L, Colombel, J, Schreiber, S, Dubinsky, M, Baert, F, Hisamatsu, T, Neimark, E, Huang, B, Liao, X, Song, A, Berg, S, Duan, W, Pang, Y, Pivorunas, V, Kligys, K, Wallace, K, D’Haens, G
Publicado 2022